Konan Medical has announced objectiveFIELD, a FDA-cleared device designed to evaluate the human visual field in a completely objective and non-contact manner.
Unlike the conventional method currently in use in most eye doctors’ offices, there is no need for any manual input from the patient. Using a patented multi-focal pupil objective perimetry method (mfPOP), objectiveFIELD tests both eyes simultaneously in only a few minutes.
objectiveFIELD has been clinically researched in Australia over more than a 12-year period with more than 16,000 examinations across normal, glaucoma, macular degeneration, diabetic retinopathy, multiple sclerosis, epilepsy, migraine, concussion, and other neuro-vision conditions.
objectiveFIELD was acquired from the Australian National University (ANU), includes novel features licensed from Seeing Machines, and is the brain-child of noted researcher Ted Maddess, PhD, with his team “The Maddess Group – Diagnostics for Eye Diseases”, at the John Curtin School of Medical Research.
Intellectual property acquired by Konan includes 15 issued patents in 9 countries, 6 patents in process, and clinical data to support a wide range of important diagnostic indications.
The worldwide premiere of objectiveFIELD will be at the American Academy of Ophthalmology Annual Meeting in Chicago from October 26-30, 2018 at Konan Medical Booth # 2515 and it will also be showcased at the American Academy of Optometry in San Antonio, TX, November 7-9, 2018.
Konan Medical USA CEO Charles Stewart said: “The initial roll-out of objectiveFIELD will feature an easy-to-use, easy-to-administer, engaging experience for the patient.
“The test is administered with both eyes open, takes only minutes to complete and represents a welcome new paradigm for patients, technicians and doctors. Additional features with supportive data are expected to be delivered as regulatory requirements are met.”
Ted Maddess, PhD added, “Konan Medical, with their expertise both in pupil tracking applications and with high precision ophthalmic diagnostic devices, was a great selection for ANU. We are excited to get objectiveFIELD to market after an extensive research, development and clinical testing phase.”
objectiveFIELD has also been clinically researched for use in concussion assessment at ANU that are thought to have visual-field manifestations.
Recently Gordon Waddington, Professor of Sports Medicine at the Australian Institute of Sport, and Professor Braden McGrath, at the University of Canberra, additionally have helped conduct novel measures of visual function related to concussion injuries with objectiveFIELD technology.
According to Marketscope’s 2018 Ophthalmic Diagnostic Equipment Report, it is expected that there will be about 149,008 perimeters in service in the global market in 2018, including 11,021 new perimeters sold annually, growing more than 2% per year, and representing more than $260,000,000 in global annual sales.
Source: Company Press Release